Parker Institute, BMS and CRI announce partnership to accelerate immuno-oncology research

The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company and the Cancer Research Institute (CRI) today announced a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks. Bristol-Myers Squibb will work closely with prominent Parker Institute and CRI scientists and researchers, soliciting clinical research

Continue Reading